Jeff Hatfield, Vividion CEO
‘Pluck those diamonds’: Bayer’s Vividion eyes up to nine oncology targets from Duke spinout
After snapping up Vividion before it could jump onto Nasdaq last August, Bayer’s preclinical ‘arms-length’ subsidiary is betting on a relatively unknown North Carolina upstart in a five-year pact.
The initial focus concerns four targets, but the deal with Durham-based Tavros Therapeutics could balloon by another five targets, which would more than double the terms from $430.5 million in milestones to a whopping $912 million. Either way, the 14-employee Tavros gets $17.5 million upfront.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
